Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Real-World study tracks myeloma Patients' adherence to carfilzomib combos

NCT ID NCT02970747

First seen Jan 04, 2026 · Last updated Apr 29, 2026 · Updated 21 times

Summary

This study looked at how consistently 359 adults with relapsed multiple myeloma followed their prescribed carfilzomib combination treatments in everyday medical practice. Researchers measured adherence and persistence to therapy, but did not test any new drugs or aim to cure the disease. The goal was to gather real-world data on treatment habits.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Centrum für Hämatologie und Onkologie Bethanien

    Frankfurt, 60389, Germany

Conditions

Explore the condition pages connected to this study.